We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 2 of 3 for:    escape bio

A Natural History Study of Patients With G2019S LRRK2 Parkinson's Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05349019
Recruitment Status : Terminated (Sponsor stopped the study)
First Posted : April 27, 2022
Last Update Posted : January 18, 2023
Sponsor:
Collaborators:
Momentum Pharma
Science 37
Information provided by (Responsible Party):
Escape Bio, Inc.

Brief Summary:
To characterize using a participant centered decentralized (at home) study featuring wearable technology and telemedicine to study disease change over time in patients with PD caused by the G2019S mutation in the LRRK2 gene and to identify a clinical endpoint(s) for disease modifying experimental therapy trials.

Condition or disease Intervention/treatment
Patients With Parkinson's Disease (PD) Caused by the p.Gly2019Ser (G2019S) Pathogenic Mutation of the Leucine-Rich Repeat Kinase 2 (LRRK2) Gene Other: Observational

Layout table for study information
Study Type : Observational
Actual Enrollment : 22 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: A Natural History Study of Patients With Parkinson's Disease (PD) Caused by the p.Gly2019Ser (G2019S) Pathogenic Mutation of the Leucine-Rich Repeat Kinase 2 (LRRK2) Gene
Actual Study Start Date : May 2, 2022
Actual Primary Completion Date : August 5, 2022
Actual Study Completion Date : August 5, 2022

Resource links provided by the National Library of Medicine


Group/Cohort Intervention/treatment
Part A/Sub Cohort A1
15 healthy participants 18-35 years of age
Other: Observational
This is an observational study to investigate the natural history of G2019S LRRK2 PD using traditional and digital methodology (digital phenotyping). Study conduct will be decentralized (at home as much as possible) consisting of two parts: Part A with Healthy Volunteers (HV) participants and Part B in patients with G2019S LRRK2 PD.

Part A/Sub Cohort A2
15 healthy participants 65-80 years of age
Other: Observational
This is an observational study to investigate the natural history of G2019S LRRK2 PD using traditional and digital methodology (digital phenotyping). Study conduct will be decentralized (at home as much as possible) consisting of two parts: Part A with Healthy Volunteers (HV) participants and Part B in patients with G2019S LRRK2 PD.

Part A/Sub Cohort A3
Control group age and sex matched to the PD participants in Part B of the study
Other: Observational
This is an observational study to investigate the natural history of G2019S LRRK2 PD using traditional and digital methodology (digital phenotyping). Study conduct will be decentralized (at home as much as possible) consisting of two parts: Part A with Healthy Volunteers (HV) participants and Part B in patients with G2019S LRRK2 PD.

Part B
60 participants with a confirmed diagnosis of Parkinson's disease and a heterozygous G2019S mutation in the LRRK2 gene
Other: Observational
This is an observational study to investigate the natural history of G2019S LRRK2 PD using traditional and digital methodology (digital phenotyping). Study conduct will be decentralized (at home as much as possible) consisting of two parts: Part A with Healthy Volunteers (HV) participants and Part B in patients with G2019S LRRK2 PD.




Primary Outcome Measures :
  1. Compare the change over 12 months in the modified Timed Up and Go (mTUG) test [ Time Frame: 12 months ]
    To compare the change over 12 months in the modified Timed Up and Go (mTUG) test, or subitems of the mTUG, recorded by video and a smartphone sensor application between participants with PD caused by the G2019S pathogenic mutation of the LRRK2 gene, and age and sex matched healthy control cohort


Secondary Outcome Measures :
  1. Evaluate the change over 12 months in linear velocity parameter in ambulation and gait. [ Time Frame: 12 months ]
    To evaluate the change over 12 months in parameter ambulation and gait including linear velocity measured in meters/second.

  2. Evaluate the change over 12 months in stride length parameter in ambulation and gait. [ Time Frame: 12 months ]
    To evaluate the change over 12 months in parameter ambulation and gait including stride length measured in meter.

  3. Evaluate the change over 12 months in cadence parameter in ambulation and gait. [ Time Frame: 12 months ]
    To evaluate the change over 12 months in parameter ambulation and gait including cadence measured in steps per minute.

  4. Evaluate the change over 12 months in double support parameter in ambulation and gait. [ Time Frame: 12 months ]
    To evaluate the change over 12 months in parameter ambulation and gait including double support time as measured in milliseconds in a real world setting using a digital insole device.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
  • Part A (Healthy Volunteers): Healthy participants aged 18-80 years of age
  • Part B (Patients with Parkinson Disease): Participants with PD caused by the G2019S pathogenic mutation of the LRRK2 gene
Criteria

Part A Inclusion Criteria (Healthy Volunteers)

Individuals eligible to participate in Part A of this study will meet all the following criteria:

  1. Willing and able to provide informed consent after the nature of the study has been explained
  2. 18-35 years of age inclusive at Screening (sub cohort A1) or 65-80 years of age inclusive at Screening (sub cohort A2)
  3. Willing and able to comply with all study procedures
  4. Sub cohort A3 participants must match the age ± 0.5 years and sex of match participant in Part B
  5. Participant must be healthy as per the investigator's assessment with no underlying clinically significant diseases (participants with hypertension, diabetes, hypercholesterolemia, and other chronic diseases associated with aging but not thought to interfere with the performance of the mTUG or other study measures may be allowed after consultation with the Medical Monitor)
  6. Participant must be able to use the Technology as described in the protocol
  7. Have access to a minimum indoor space of 6 meters by 2 meters (or approximately 20 feet by 7 feet) to carry out the mTUG
  8. Agree to retain the same level of activity throughout the study and not have plans to stop/start or increase or decrease any exercise programs
  9. Have reliable access to working WiFi internet or willingness to use a provided cellular internet connection device
  10. Agree to refrain from all alcohol and cannabinoid products within 24 hours prior to performing the mTUG assessment (i.e., three non consecutive days during study Week two, and Weeks two and three of the run in period)

Part A Exclusion Criteria (Healthy Volunteers)

Individuals who meet any of the following exclusion criteria will not be eligible to participate in the study:

  1. History of mobility, gait, or ambulation problems (defined as mobility limitations that impact walking on a daily basis)
  2. History of neurological disease
  3. Any elective surgery planned during the study duration, approximately 12-15 months from Screening
  4. History of significant head injury within the past 5 years (head injury with loss of consciousness or requiring greater than 24 hours in hospital in relation to head injury)
  5. History of alcohol use disorder or other substance abuse disorder (excluding tobacco use), according to the Diagnostic and Statistical Manual of Mental Disorders 5th Edition (DSM-5) in the past 10 years
  6. Body Mass Index (BMI) (calculated from self reported height and weight) of greater than 35
  7. Pregnant or planning to become pregnant in the next 24 months
  8. Has a concurrent disease or condition that, in the view of the investigator, places the subject at high risk of poor treatment compliance or of not completing the study, or would interfere with study participation or would affect safety

Part B Inclusion Criteria (PD Patients)

Individuals eligible to participate in Part B of this study must meet all the following criteria:

  1. Willing and able to provide informed consent after the nature of the study has been explained
  2. Willing and able to comply with all study procedures
  3. Have confirmed diagnosis of PD documented in medical records according to UK Brain Bank criteria
  4. Confirmed G2019S mutation(s) in the LRRK2 gene either by evidence recorded in medical record with report from accredited laboratory, or through another accredited genetic testing program, or other partner laboratory. Up to 10 participants with homozygous mutations may be enrolled in addition to the 60 participants with heterozygous mutation
  5. Hoehn and Yahr Scale Score 1-3
  6. Physically and cognitively able to complete protocol specified tasks independently or with some assistance
  7. If assistance is required for completion of tasks (e.g., help with the Technology), a caregiver or volunteer must be fully available to assist the participant for the duration of the study
  8. Ability to complete the mTUG without the use of a cane or walker and without a personal assistant
  9. Ability to complete the mTUG which is not impacted by comorbidities (e.g., participant should not have underlying, clinically significant cardiac or respiratory disease, or musculoskeletal disease). Non-progressive diseases of these organ systems must be approved by the Medical Monitor prior to enrollment; for example, mild to moderate osteoarthritis may be allowable
  10. Have access to a minimum indoor space of 6 meters by 2 meters (or approximately 20 feet by 7 feet) to carry out the mTUG
  11. A helper or participant is required to be present during the performance of mTUG, if the participant has had more than one fall in the past 12 months
  12. The participant's general health status is acceptable for participation in the study (per their physician)
  13. Working WiFi internet or willing to use a provided cellular internet connection device
  14. Participant must agree to refrain from all alcohol and cannabinoid products within 24 hours prior to performing the mTUG (i.e., three non consecutive days during study Week two, and Weeks two and four of the run in period)

Part B Exclusion Criteria (PD Patients)

Individuals who meet any of the following exclusion criteria will not be eligible to participate in the study:

  1. Any mobility, gait, or ambulation problems other than those related to PD
  2. Any deep brain stimulation in situ or planned during the study duration, approximately 12-15 months from Screening
  3. Any planned changes in physiotherapy or exercise therapy
  4. Planned initiation of, or changes in, cognitive behavioral therapy
  5. Any elective planned surgery during the study duration, approximately 12-15 months from Screening
  6. History of significant head injury within the past 5 years (head injury with loss of consciousness or requiring greater than 24 hours in hospital in relation to head injury)
  7. History of frequent falls (classified as one fall every 1 month)
  8. Any other genetic PD causing mutations, for example, a pathogenic GBA mutation
  9. History of alcohol use disorder or other substance abuse disorder (excluding tobacco use), according to the DSM-5 in the past 10 years
  10. Any other serious concomitant diseases unrelated to PD (e.g., other neurological diseases of any kind, renal failure, liver failure, active cancer)
  11. BMI (calculated from self reported height and weight) of greater than 35
  12. Pregnant or planning to become pregnant in the next 24 months
  13. Has a concurrent disease or condition that, in the view of the investigator, places the subject at high risk of poor treatment compliance or of not completing the study, or would interfere with study participation or would affect safety

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05349019


Locations
Layout table for location information
United States, California
Science 37
Culver City, California, United States, 90230
Sponsors and Collaborators
Escape Bio, Inc.
Momentum Pharma
Science 37
Investigators
Layout table for investigator information
Study Chair: Carrolee Barlow, MD, PhD Escape Bio, Inc.
Publications:
Layout table for additonal information
Responsible Party: Escape Bio, Inc.
ClinicalTrials.gov Identifier: NCT05349019    
Other Study ID Numbers: ESBG2019S-001
First Posted: April 27, 2022    Key Record Dates
Last Update Posted: January 18, 2023
Last Verified: August 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Escape Bio, Inc.:
G2019S LRRK2 mutation
Additional relevant MeSH terms:
Layout table for MeSH terms
Parkinson Disease
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Synucleinopathies
Neurodegenerative Diseases